To browse Academia. Background: Recent studies have suggested that statins possess diverse immune modulatory and anti-inflammatory properties. As statins might attenuate inflammation, statin therapy has been hypothesized to reduce mortality in HIVinfected individuals. We therefore used a Danish nationwide cohort of HIV-infected individuals to estimate the impact of statin use on mortality before and after a diagnosis of cardiovascular disease, chronic kidney disease or diabetes.
Background: It is unknown whether statin use among people living with HIV results in a reduction in all-cause mortality. We aimed to evaluate the effect of statin use on all-cause mortality among people living with HIV. We included randomised, quasi-randomised trials and prospective cohort studies that examined the association between statin use and cardio-protective and mortality outcomes among people living with HIV. Two reviewers independently abstracted the data.
.jpg?itok=x9PtUxbG "Escort girls Les Mureaux")
Hazard ratios HRs were pooled using empirical Bayesian random-effect meta-analysis. A number of sensitivity analyses were conducted.
Results: We included seven studies with a total of 35, participants. The probability that statin use conferred a moderate mortality benefit i. Downweighting and excluding the lower quality studies resulted in a more conservative estimate of the pooled HR. Conclusion: Statin use appears to confer moderate mortality benefits in people living with HIV. The rate of new human immunodeficiency virus HIV infections globally is alarming. Moreover, virally suppressed patients still experience immune activation associated with HIV migration from reservoir sites.
Statins are widely recommended as therapeutic agents to control ART-related CVD; however, their impacts on the cluster of differentiation CD 4 count and viral load are inconsistent. To assess the effect of statins on markers of HIV infections, immune activation and cholesterol, we thoroughly reviewed evidence from randomised controlled trials.
